Evidence map›Paper›PMID 38757258›Full record

ArticleInfluenza and other respiratory viruses2024

Respiratory Syncytial Virus and Influenza Infections in Children in Ulaanbaatar, Mongolia, 2015-2021.

Lien Anh Ha Do, Naranzul Tsedenbal, Chimidregzen Khishigmunkh, Bazarkhuu Tserendulam, Lkhagvadorj Altanbumba, Dashtseren Luvsantseren, Munkhchuluun Ulziibayar, Bujinlkham Suuri, Dorj Narangerel, Bilegtsaikhan Tsolmon and 9 more

Abstract read
In one paragraph

Article in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Lien Anh Ha DoNew Vaccines Group, Murdoch Children's Research Institute, Melbourne, Australia.ORCID 0000-0002-2401-8980
Naranzul TsedenbalVirology Department, National Center of Communicable Diseases, Ulaanbaatar, Mongolia.
Chimidregzen KhishigmunkhVirology Department, National Center of Communicable Diseases, Ulaanbaatar, Mongolia.
Bazarkhuu TserendulamVirology Department, National Center of Communicable Diseases, Ulaanbaatar, Mongolia.
Lkhagvadorj AltanbumbaVirology Department, National Center of Communicable Diseases, Ulaanbaatar, Mongolia.
Dashtseren LuvsantserenVirology Department, National Center of Communicable Diseases, Ulaanbaatar, Mongolia.
Munkhchuluun UlziibayarVirology Department, National Center of Communicable Diseases, Ulaanbaatar, Mongolia.
Bujinlkham SuuriVirology Department, National Center of Communicable Diseases, Ulaanbaatar, Mongolia.
Dorj NarangerelNational Center for Communicable Diseases, Ministry of Health, Ulaanbaatar, Mongolia.
Bilegtsaikhan TsolmonVirology Department, National Center of Communicable Diseases, Ulaanbaatar, Mongolia.
Sodbayar DemberelsurenExpanded Program on Immunization, World Health Organization, Ulaanbaatar, Mongolia.
Casey L PellTranslational Microbiology Group, Murdoch Children's Research Institute, Melbourne, Australia.
Sam MannaTranslational Microbiology Group, Murdoch Children's Research Institute, Melbourne, Australia.
Catherine SatzkeDepartment of Paediatrics, The University of Melbourne, Parkville, Australia.
Cattram NguyenNew Vaccines Group, Murdoch Children's Research Institute, Melbourne, Australia.
Tuya MungunVirology Department, National Center of Communicable Diseases, Ulaanbaatar, Mongolia.
Claire von MollendorfNew Vaccines Group, Murdoch Children's Research Institute, Melbourne, Australia.
Darmaa BadarchVirology Department, National Center of Communicable Diseases, Ulaanbaatar, Mongolia.
Kim MulhollandNew Vaccines Group, Murdoch Children's Research Institute, Melbourne, Australia.

Funding

Gates Foundation OPP1169299Gavi, The Vaccine Alliance PP61690717A2World Health Organization 001
6 · The paper itself

Abstract

backgroundData available for RSV and influenza infections among children < 2 years in Mongolia are limited. We present data from four districts of Ulaanbaatar from April 2015 to June 2021.

methodsThis study was nested in an enhanced surveillance project evaluating pneumococcal conjugate vaccine (PCV13) impact on the incidence of hospitalized lower respiratory tract infections (LRTIs). Our study was restricted to children aged < 2 years with arterial O

resultsAmong 5705 patients, 2113 (37.0%) and 386 (6.8%) had RSV and influenza infections, respectively. Children aged 2-6 months had a higher percentage of very severe RSV infection compared to those older than 6 months (42.2% versus 31.4%, p-value Fisher's exact = 0.001). S.p. carriage was detected in 1073/2281 (47.0%) patients. Among S.p. carriage cases, 363/1073 (33.8%) had S.p. and RSV codetection, and 82/1073 (7.6%) had S.p. and influenza codetection. S.p. codetection with RSV/influenza was not associated with more severe LRTIs, compared to only RSV/influenza cases.

conclusionIn Mongolia, RSV is an important pathogen causing more severe LRTI in children under 6 months of age. Codetection of RSV or influenza virus and S.p. was not associated with increased severity.

Indexed as

Influenza, HumanRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsChild, PreschoolFemaleHospitalizationHumansIncidenceInfantInfant, NewbornMaleMongoliaNasopharynxRespiratory Tract InfectionsStreptococcus pneumoniaeinfluenza viruslower respiratory tract infectionsrespiratory syncytial virus

Identifiers

PMID38757258
PMCPMC11099724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.